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Pancreatic cancer is the fourth leading cause of death among all cancers. Lack of 
effective screening and treatment modalities lends to poor prognosis and high mortality. For 
these reasons new therapeutic regimens are desperately needed for the treatment of 
pancreatic cancer. Minnelide, which is a prodrug of triptolide, is currently being evaluated as a 
potential drug therapy for pancreatic cancer. Early preclinical test has shown that triptolide is 
highly effective of reducing tumor progression and metastases. Despite showing clinical 
efficacies the mechanism of triptolide is not fully understood.  
One of the targets of triptolide reported is c-Myc. c-Myc has been associated with 
various aggressive tumors including pancreatic cancer. We hypothesize that triptolide maybe 
suppressing the expression of c-Myc by inhibiting the binding of its transcription factors or 
coactivators to the promoter and/or enhancer regions of the c-Myc gene. The Far UpStream 
Element binding protein 1 (FBP1) is a potential regulatory element that may be affected by 
triptolide.  
In this study, we investigated whether triptolide regulates c-Myc expression by 
inhibiting FBP-1 protein expression at the transcription and/or protein level. We performed an 
RNA sequence to determine global regulation of transcriptome in response to triptolide 
treatment. In addition, we determined the effects of triptolide on c-Myc, FBP1 and FIR protein 
expression. We found that 100nM of triptolide inhibited gene expression of c-Myc, FBP1, FIR 
and XBP by 2.4, 1.3, 3.5, and 1.4 fold respectively (p<0.05, n=2). This finding is consistent with a 
decrease in protein expression of c-Myc (53%) and FIR (83%) only. There was no effect of FBP-1 
protein expression with triptolide treatment. This data suggests that inhibition of c-Myc 
expression is independent of FBP-1 expression however this does not rule out the possibility of 
triptolide ability to alter the activity of FBP-1 preventing it from binding to TFIIH at the active 
XPB subunit. An attempt to create a XPB CRISPR knockout clone resulted in a potentially lethal 
mutation in PC cells. Additional studies are further needed to elucidate the mechanisms of 
triptolide but, these results suggest that XPB may serve as an effective target for future 
therapy.    
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 Each year approximately 43,000 new cases of pancreatic cancer (PC) are reported in the 
United States, which accounts for about 2.8% of all cancers1. PC has one of the highest 
mortality rates among all malignancies. The National Cancer Institute estimates that the mean 
survivability for PC patients to be approximately 3 - 6 months and the 5-year survivability rate 
to be 6.7%1. Lack of effective screening and treatment modalities lends to poor prognosis and 
high mortality. 
 Surgical resection is the ideal course of action for PC.  However, surgical candidacy 
highly depends on the location of the tumor (i.e. pancreatic head, body, tail or ampulla), 
presence of metastases and the degree of vascular invasion2,3. Less than 20% of diagnosed 
pancreatic tumors are resectable4. Chemotherapy with Folfirinox or combination treatment 
with gemcitabine and nab paclitaxel is the current recommended chemotherapeutic treatment 
for PC. Clinical studies have shown that current treatments utilized for PC provide poor 
objective response rates and does not significantly improve survival5. Thus, new clinical studies 
are desperately needed to define better treatment strategies for this lethal disease. 
Triptolide is a natural compound that is extracted from a Chinese medicinal plant, 
Tripterygium wilfordii. Triptolide has been shown to induce apoptosis in a number of cancer 
cells including pancreatic cancer6-8. Early preclinical studies for minnelide, a prodrug for 
triptolide has shown promising results for treating pancreatic cancer. Data have reported as 
much as 60% reduction in tumor size in animal studies9,10. Triptolide has been implemented in 
down regulation of proliferation by inhibiting pro-mitotic growth factor VEGF and COX-211. It 
also induces cellular apoptosis by down regulation of heat shock protein 70 by disrupting the 
activity of Sp1 and increase expression of miR142-3p12,13. Triptolide is currently under phase I 
clinical trials.  However, despite showing clinical efficacies with strong specificity to tumor cells 
the mechanism by which triptolide induces cell death of pancreatic cancer needs to be further 
explored in order to refine optimal treatment strategies for PC. 
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The transcriptional factor, c-Myc has been associated with various aggressive malignant 
tumors including pancreatic cancer14. High level expression of c-Myc has been shown to cause 
increase binding of pro-mitogenic transcriptional factor to their respective promoters and 
enhancer targets thereby causing gene amplification in tumor cells15 to promote cell growth 
and metabolism16. Normal binding of FBP1 to the FUSE sequence upstream of the c-Myc 
promotor brings FBP1 into the proximity of the transcription machinery and interacts with 
transcription factor 2 helicase (TFIIH) and optimizes transcription causing an upsurge in c-Myc 
expression17 during mitosis. The subsequent rise in FBP1 binding in turn activates a negative 
feedback loop and recruit the FBP1 interacting repressor (FIR) which binds XPB; a helicase 
subunit of TFIIH thereby hindering TFIIH from activation by FBP1 and inhibit the expression of  
c-Myc to restore baseline. Small changes in FBP-FIR affinity can lead to drastic unregulated 
expression of c-myc thus leading to rapid cell proliferation and pathogenesis. In this study we 
investigated whether triptolide regulates c-Myc expression by inhibiting FBP1 protein 













Experiments were conducted using commercially available MIA-PaCa2 cell lines 
purchased from American Type Culture Collection grown in DMEM supplemented with 10% FBS 
and 0.1% antibiotics. Cells were passaged every 3 days at a ratio 1:3. All experiments were 
conducted with cells passage less than 12.  
RNA Sequencing 
To determine the global gene regulation by triptolide on the super-enhancer region of c-
Myc, we performed RNA sequencing on MIA-PaCa2 cell lines for both untreated and treated 
with triptolide. PC cells were seeded at 500,00 cells per well for 24 hours on a 6 well plate and 
were then treated with 100nM of triptolide for 6 hours. RNA isolation and cDNA library were 
obtained using the Illumina protocol: TrueSeq RNA sample preparation v2 LS. Samples were 
then sequenced using Novogene RNA-sequencing services. Sample size consisted of n=2 and 
data were analyzed using DEseq analysis software. 
c-Myc Expression 
We are particularly interested in whether any potential anti-mitogenic effect of 
triptolide is caused by the down regulation of c-Myc. To measure the expression level of c-Myc 
we determined both the mRNA expression and protein level of c-Myc in untreated and 
triptolide treated cultures via RT-PCR and Western blotting, respectively. We used c-Myc 
primers obtained from Qiagen (Quantitect primer assay) gene bank NM_002467 (Forward 
Primer = AAACACAAACTTGAACAGCTAC) for PCR quantification. Anti-c-Myc (Y69) rabbit 
monoclonal from Abcam product# ab32072 was used for total protein expression of c-Myc.   
Expression of FBP and FIR  
The binding of FUBP to the FUSE sequence upstream of c-Myc promoter optimizes and 
enhances its transcription. To determine if the level of FUBP is affected by triptolide we 
evaluated this regulation at a transcription and translation level. Triptolide treated samples 
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were assessed for RNA and protein expression levels using RT-PCR and Western blotting for FBP 
and FIR and XBP (ERCC3). Primers were obtained from Qiagen (Quantitect primer assay) and 
anti-FBP1 antibody was from Pierce-antibodies (# PA5-30291). 
XPB KO Mia-PaCa2 cells using CRISPR 
Methods used were adapted from Ran et al. published in Nature Protocol18. Plasmid 
were obtained from Addgene (plasmid ID: 48138); pSpCas9(BB)-2A-GFP. Oligos sgRNA sequence 
targeting XPB at exon 9 Fwd: 5’-CACCGGCTCCATATTCATCCACTT-3’; Rev: 5’-
AAACAAGTGGATGAATATGGAGC-3’ (D54H). Cas9-D54H constructs were sequenced using a U6 
forward primer to verify clone sequence containing guide RNA. Functional validation was 
performed by transfecting HEK293FT cells and detecting indel mutations by surveyor nuclease 
assay. Mia-PaCa-2 cells were then transfected to establish a XPB KO line and treated with 





Triptolide suppresses c-Myc expression at the mRNA level 
We determined the effects of triptolide on global gene regulation by performing RNA 
sequencing on MIA-PaCa2 cells treated with 100nM for 24 hours. We found that triptolide 
decreased mRNA expression by 2.4-fold when compared to control (Table 1: p<0.001, n=2). 
There was also a significant decrease in the mRNA expression of ERCC3 (XPB), PUF60 and FBP1 
by 1.4, 3.5 and 1.3-fold respectively.  
Triptolide downregulates the expression of c-Myc, FUBP and FIR at the protein level 
We next investigated whether the effects of triptolide on gene activity is correlated with 
regulation of translation into mRNA and protein expression. We found that 100nM of triptolide 
decreased c-Myc protein expression by 53% (Figure 1A: p<0.05, n=3) when compared to 
control. Doses less than 10nM had no effect on protein expression. However, at doses above 
25nM we observed a negative dose response (Figure 1 panel D).   
FBP-1 is a known enhancer of c-Myc which binds the far upstream element in the promotor 
region approximately 1.5kb upstream from the start codon. No significant differences were 
seen in FBP-1 protein expression with any of triptolide doses used (Figure 1B). There was a 
decreasing trend in FIR protein expression with an 83% reduction seen with 100nM triptolide 
treatment (Figure 1C: p<0.05 n=3).  
Knock out of XPB in Mia-PaCa2 pancreatic cancer cells is potentially lethal 
Next, we wanted to determine whether triptolide could inhibit the ability of FBP-1 to bind 
to XPB, the active site of TFIIH. We used CRISPR to create a knockout mutant which would 
potentially create a resistant strain of pancreatic cancer cells to triptolide. Transfected HEK293T 
cells treated with endonuclease resulted in a mismatch sequence as indicated by a tertiary 
band at 350kb and 250kb in lane PsP-Cas9 sgRNA + endonuclease compared to no nuclease. 
(Figure 2A black arrow). Transfection of HEK293T control cells resulted in a low transfection 
rate of approximately 10% (Figure 3D). However, when attempting to transfected MiaPaca2 
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cells we observed poor cell morphology with high level of detached cells transfected with Cas9 
clone (Figure 2C black arrow). We were unable to detect fluorescence marker post transfection 
















Abbreviations: C-Myc ; ERCC3 sequence for protein XPB an essential subunit for transcription II 
helicase . FBP1 = FUSE binding protein, PUF60 = poly U binding splicing factor 60 which codes 
for FBP interacting repressor.  RNA sequence data was statistically analyzed using DESeq2 with 












Figure 1: MiaPaca2 treated with triptolide [0 – 100nm] for 6 hours and accessed for protein 
expression. Presented as mean + SEM of protein / b-Actin ratio  A.) C-Myc, B.) FBP-interacting 
repressor (FIR) and C.) far upstream element binding protein (FBP-1) in response to treatment 
with 1nm, 10nm and 100nm of triptolide. * p<0.001 vs. Control.  Panel D shows representative 















Figure 2:  Functional validation of HEK293T transfection with PsP-Cas9 sgRNA clone using 
surveyor assay to detect single base mismatch (Figure 3A lanes 4 and 5). (+) signifies the 
addition of endonuclease (Panel A lanes 3 and 5) and absence (-) of endonuclease (Figure 3A 
lanes 2 and 4). Transfection control:HEK293T (Figure 3B, 3D) and MiaPaCa1(Figure 3C, 3E) with 
PsP-Cas9 clone of image by light microscopy  and fluorescence overlay. Arrow in Figure 3C 
shows round cells detached from the culture plate with poor morphology. 
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Discussion 
Triptolide has been shown to have various anticancer effects in a number of 
malignancies including pancreatic adenocarcinoma (PAC). Studies have shown that triptolide 
antimitogenic effects are associated with dysregulation of heat-shock protein, caspaces, NF-kB, 
c-Myc and also enhances the synergistic effects with other chemotherapeutics. However, 
despite these findings the exact mechanism still remains elusive. To our knowledge this study is 
the first to investigate super-enhancers as a potential mechanism of triptolide regulating c-Myc 
in PAC. 
Dysregulation and enhanced expression of c-Myc has been well characterized in 
pancreatic adenocarcinoma19. In this study investigated the far upstream binding protein 1 
(FBP-1) as a potential target of triptolide. Normally binding of FBP-1 to the Far upstream 
element (FUSE) upstream of the c-Myc promotor brings FBP-1 into the proximity of the 
transcription machinery and interacts with TFIIH and optimizes transcription. This subsequent 
rise in FBP-1 binding in turns activates a negative feedback loop and recruit the FBP interacting 
repressor which binds XPB; a helicase subunit of TFIIH thereby hindering TFIIH from activation 
by FBP.  
We observed that treating PC with 100nM of triptolide for 6 hours was effective in 
reducing c-Myc protein expression by 2.4 fold (p<0.05, n=3) when compared to no treatment. 
This finding was consistent with decreasing protein expression of c-Myc by 53%. We found that 
although triptolide decreased the mRNA level of FBP-1 this did not result in decreased protein 
expression. This suggest that triptolide regulation of c-Myc may not be dependent on the 
expression of FBP-1. Treatment with 100nM triptolide significantly suppressed FIR expression at 
the transcription level. This suggests that although tripolide may not significantly inhibit FBP-1 
expression, it may be affecting its ability to interact with TFIIH at a sufficient level to potentiate 
the negative feedback loop of FIR. XPB maybe a potential target of triptolide where we also saw 
a decrease in mRNA expression. 
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To investigate whether triptolide has a direct effect on XBP and or FBP-1 ability to 
interact with XPB we attempted to create an XPB knock clone using CRISPR. We were successful 
in ligating a single guide RNA into a pSp-Cas9 plasmid containing a GFP marker. Using this 
plasmid clone we were able to transfect 293T cells and introduce the mutation; however, 
attempts to transfect MiaPaCa2 cell lines have been unsuccessful (Figure 2). It is possible that 
the mutation introduced into MiaPaCa2 creating an XPB KO may prove to be lethal mutation 
however, it is important to note that XPB function is necessary but not essential for cell 
replication. This study supports that triptolide may be acting on the super enhancer FBP-1 in 
regulating c-Myc expression and may serve as a potential target as a potential therapeutic 
modality for PAC treatment. Despite these finding additional studies are further needed to 
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